Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 64-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 103-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

By Pigott Teresa A.   Prakash Apurva   Arnold Lesley M.   Aaronson Scott T.   Mallinckrodt Craig H.   Wohlreich Madelaine M.  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1303-1318

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

By Colonna Lucien   Andersen Henning Friis   Reines Elin Heldbo  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1659-1668

Informa Healthcare

Access to resources Recommend Favorite

A Randomized Trial on the Acute and Steady‐State Effects of a New Antidepressant, Vortioxetine (Lu AA21004), on Actual Driving and Cognition

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 6, 2013-06 ,pp. : 493-501

John Wiley & Sons Inc

Access to resources Recommend Favorite